<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124004</url>
  </required_header>
  <id_info>
    <org_study_id>NOADB_debridement</org_study_id>
    <nct_id>NCT03124004</nct_id>
  </id_info>
  <brief_title>Evaluation of the Intra- and Post- Operative Bleeding After Periodontal Debridement in Direct Anticoagulant Patients</brief_title>
  <acronym>NOADB_db</acronym>
  <official_title>Evaluation of the Intra- and Post- Operative Bleeding After After Periodontal Debridement in Direct Oral Anticoagulation Patients: a Longitudinal Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Trieste</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct Oral Anticoagulants were recently approved for medical treatment of several condition
      such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting
      sometimes the conventional oral anticoagulants. The aim of the present study is to observe
      the possible difference in intra-operative and post-operative bleeding events for periodontal
      debridement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many protocols of drug suspension for surgical procedure has been designed, since the
      introduction of anticoagulant or antiplatelet medications. Nowadays it is not certain if
      suspension could give more costs than benefits for the clinical procedure itself. With the
      recent development of the Direct Oral Anticoagulant it is still unclear whether these
      medications might bring more bleeding events in the intra-operative and post-operative phase
      after periodontal causal therapy, equal to, or more than Oral Anticoagulant Therapy. The
      purpose of this study is to assess the degree of intra- and post-operative bleeding
      complication between direct oral anticoagulant therapy patients and Oral Anticoagulant
      Therapy patients for periodontal debridement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2016</start_date>
  <completion_date type="Anticipated">November 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>intra-operative bleeding</measure>
    <time_frame>30 minutes</time_frame>
    <description>intra-operative bleeding is registered as follows: mild if stopped in 20 seconds; medium: if stopped after not more than one minute; severe: if not stopped.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-operative bleeding events</measure>
    <time_frame>1 week</time_frame>
    <description>a questionnaire is given to the patient to register post-operative bleeding events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>oral health status</measure>
    <time_frame>1 week before</time_frame>
    <description>examination of the oral cavity, registration of periodontal indices</description>
  </other_outcome>
  <other_outcome>
    <measure>cardiological assessment</measure>
    <time_frame>1 week before</time_frame>
    <description>registration of the Atrial Fibrillation Stroke Risk score</description>
  </other_outcome>
  <other_outcome>
    <measure>bleeding risk assessment</measure>
    <time_frame>1 week before</time_frame>
    <description>registration of the Score for Major Bleeding Risk score</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Anticoagulant-induced Bleeding</condition>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>Direct Oral Anticoagulants</arm_group_label>
    <description>assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral anticoagulant therapy</arm_group_label>
    <description>assuming Coumadin or Sintrom; undergoing periodontal debridement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>periodontal debridement</intervention_name>
    <description>with ultrasonic device supragingival and subgingival full-mouth debridement is provided</description>
    <arm_group_label>Direct Oral Anticoagulants</arm_group_label>
    <arm_group_label>oral anticoagulant therapy</arm_group_label>
    <other_name>subgingival scaling</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiovascular patient assuming oral anticoagulant therapy (conventional or direct)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Direct Oral Anticoagulant

        Inclusion Criteria:

          1. Male and female patients at 20 or more years of age.

          2. Healthy patients (â‰¤ American Society of Anesthesiologists 3).

          3. Regular oral anticoagulant therapy assumed from at least 3 months with the following
             molecula: Dabigatran (PRADAXA), Rivaroxaban (XARELTO), Apixaban (ELIQUIS), Edoxaban
             (LIXIANA).

          4. Indication for extraction of a single tooth.

          5. No other contraindications for tooth extraction.

          6. Accepted platelet count within 7 days prior to the procedure has to be &gt; 50000 mg/dl.

          7. Signed informed consent.

        Exclusion Criteria:

          1. Smoke &gt; 10 cigarettes per day.

          2. Assumption of any antiplatelet medication.

          3. Assumption of Heparin medication.

          4. Assumption of oral anticoagulant medications (Warfarin, Coumadin).

          5. Wash-out period after antiplatelet or Heparin medication at least 15 days.

          6. Assumption of food or drugs that may alter direct oral anticoagulant blood values.

          7. Uncontrolled Hypertension.

          8. Uncontrolled Diabetes

          9. Chronic Hepatitis and/or reduction of hepatic function

         10. Coagulopathy (in excess of defect)

         11. Anamnestically known intolerance to one of the drugs applied or to their ingredients
             or to drugs of similar chemical structure.

         12. Head and neck radiotherapy (previous 10 years).

         13. Chemotherapy (previous 2 years).

         14. Participation of the patient in another clinical trial within the last four weeks
             before enrollment in this trial.

         15. Incapability of assessing essence and possible consequences of the trial (e.g.
             alcoholism).

         16. Pregnant or breastfeeding women.

         17. Evidence suggesting that the patient is not likely to follow the study protocol (e.g.
             lack of compliance).

        Oral Anticoagulant Therapy

        Inclusion Criteria:

          1. Male and female patients at 20 or more years of age.

          2. General health status (&lt; American society of anesthesiologist a 3).

          3. Regular oral anticoagulant therapy assumed from at least 3 months with the following
             molecula: Warfarin (COUMADIN), acenocoumarol (SINTROM).

          4. Indication for extraction of a single tooth.

          5. No contraindications for tooth extraction.

          6. Accepted platelet count within 7 days prior to the procedure has to be &gt; 50000 mg/dl.

          7. International Normalized Ratio measured within 7 days prior to the procedure should
             between 2.0 and 3.0.

          8. No diet changes within the week before blood sampling (avoiding interacting food)

          9. Signed informed consent.

        Exclusion Criteria:

          1. Smoke &gt; 10 cigarettes per day.

          2. Assumption of any antiplatelet medication.

          3. Assumption of any Heparin medication.

          4. Assumption of any direct oral anticoagulant medication.

          5. Uncontrolled Hypertension.

          6. Uncontrolled Diabetes.

          7. Chronic Hepatitis and/or reduction of hepatic function

          8. Coagulopathy (in excess of defect)

          9. Wash-out period after antiplatelet or Heparin medication at least 15 days.

         10. Anamnestically known intolerance to one of the drugs applied or to their ingredients
             or to drugs of similar chemical structure.

         11. Assumption of food or drugs that may alter oral anticoagulant blood values.

         12. Head and neck radiotherapy (previous 10 years).

         13. Chemotherapy (previous 10 years).

         14. Participation of the patient in another clinical trial within the last four weeks
             before enrollment in this trial.

         15. Incapability of assessing essence and possible consequences of the trial (e.g.
             alcoholism).

         16. Pregnant or breastfeeding women.

         17. Evidence suggesting that the patient is not likely to follow the study protocol (e.g.
             lack of compliance).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Di Lenarda, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federico Berton, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fulvia Costantinides, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaetano Castronovo, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Di Lenarda, Prof.</last_name>
    <phone>0403992254</phone>
    <phone_ext>0039</phone_ext>
    <email>rdilenarda@units.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federico Berton, Dr.</last_name>
    <phone>0403992020</phone>
    <phone_ext>0039</phone_ext>
    <email>fberton@units.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica Odontoiatrica e Stomatologica</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Di Lenarda, Prof.</last_name>
      <phone>0403992254</phone>
      <phone_ext>0039</phone_ext>
      <email>rdilenarda@units.it</email>
    </contact>
    <contact_backup>
      <last_name>Federico Berton, Dr.</last_name>
      <phone>0403992020</phone>
      <phone_ext>0039</phone_ext>
      <email>fberton@units.it</email>
    </contact_backup>
    <investigator>
      <last_name>Fulvia Costantinides, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaetano Castronovo, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731944/</url>
    <description>a discussion paper on clinical implications of oral anticoagulants</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Trieste</investigator_affiliation>
    <investigator_full_name>prof. Roberto Di Lenarda</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>direct oral anticoagulant</keyword>
  <keyword>oral anticoagulant therapy</keyword>
  <keyword>periodontal disease</keyword>
  <keyword>periodontal debridement</keyword>
  <keyword>ultrasonic periodontal debridement</keyword>
  <keyword>ultrasonic scaling</keyword>
  <keyword>periodontal scaling</keyword>
  <keyword>subgingival scaling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

